Результати пошуку - Cui, Chengxu

Comparison of S‐1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single‐cente... за авторством Jiang, Zhichao, Sun, Yongkun, Zhang, Wen, Cui, Chengxu, Yang, Lin, Zhou, Aiping

Отримати повний текст Отримати повний текст Отримати повний текст

XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer за авторством CUI, CHENGXU, SHU, CHANG, YANG, YI, LIU, JUNBAO, SHI, SHUPING, SHAO, ZHUJUN, WANG, NAN, YANG, TING, HU, SONGNIAN

Отримати повний текст Отримати повний текст Отримати повний текст

Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial за авторством Zhang, Wen, Du, Chunxia, Sun, Yongkun, Yang, Lin, Cui, Chengxu, Jiang, Zhichao, Wang, Chengfeng, Wang, Jinwang, Zhou, Aiping

Отримати повний текст Отримати повний текст Отримати повний текст

The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer за авторством Song, Yan, Qu, Tao, Zhang, Honggang, Sun, Yongkun, Cui, Chengxu, Chi, Yihebali, Zhang, Wen, Wang, Xingyuan, Yang, Lin

Отримати повний текст Отримати повний текст Отримати повний текст

UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens за авторством Cui, Chengxu, Shu, Chang, Cao, Dandan, Yang, Yi, Liu, Junbao, Shi, Shuping, Shao, Zhujun, Wang, Nan, Yang, Ting, Liang, Hao, Zou, Shanshan, Hu, Songnian

Отримати повний текст Отримати повний текст Отримати повний текст

Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy за авторством Shang, Bingqing, Cao, Chuanzhen, Jiang, Weixing, Shi, Hongzhe, Bi, Xingang, Cui, Chengxu, Shou, Jianzhong, Zheng, Shan, Zhang, Jin, Zhou, Aiping, Li, Changling, Ma, Jianhui

Отримати повний текст Отримати повний текст Отримати повний текст

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial за авторством Qin, Shukui, Bi, Feng, Gu, Shanzhi, Bai, Yuxian, Chen, Zhendong, Wang, Zishu, Ying, Jieer, Lu, Yinying, Meng, Zhiqiang, Pan, Hongming, Yang, Ping, Zhang, Helong, Chen, Xi, Xu, Aibing, Cui, Chengxu, Zhu, Bo, Wu, Jian, Xin, Xiaoli, Wang, Jufeng, Shan, Jinlu, Chen, Junhui, Zheng, Zhendong, Xu, Li, Wen, Xiaoyu, You, Zhenyu, Ren, Zhenggang, Liu, Xiufeng, Qiu, Meng, Wu, Liqing, Chen, Feng

Отримати повний текст Отримати повний текст Отримати повний текст

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label pha... за авторством Xu, Jianming, Li, Yi, Fan, Qingxia, Shu, Yongqian, Yang, Lei, Cui, Tongjian, Gu, Kangsheng, Tao, Min, Wang, Xiuwen, Cui, Chengxu, Xu, Nong, Xiao, Juxiang, Gao, Quanli, Liu, Yunpeng, Zhang, Tao, Bai, Yuxian, Li, Wei, Zhang, Yiping, Dai, Guanghai, Ma, Dong, Zhang, Jingdong, Bai, Chunmei, Huang, Yunchao, Liao, Wangjun, Wu, Lin, Chen, Xi, Yang, Yan, Wang, Junye, Ji, Shoujian, Zhou, Hui, Wang, Yan, Ma, Zhuo, Wang, Yanqi, Peng, Bo, Sun, Jiya, Mancao, Christoph

Отримати повний текст Отримати повний текст Отримати повний текст